Surrozen, Inc. (NASDAQ:SRZN) Short Interest Update

Surrozen, Inc. (NASDAQ:SRZN) was the recipient of a significant growth in short interest in December. As of December 15th, there was short interest totalling 45,400 shares, a growth of 33.9% from the November 30th total of 33,900 shares. Based on an average trading volume of 33,200 shares, the days-to-cover ratio is presently 1.4 days. Currently, 1.9% of the shares of the stock are short sold.

Surrozen Stock Performance

Shares of NASDAQ:SRZN traded down $0.88 on Friday, reaching $13.90. 48,850 shares of the company were exchanged, compared to its average volume of 18,479. The company has a 50-day moving average of $10.44 and a 200-day moving average of $9.76. Surrozen has a 1-year low of $6.00 and a 1-year high of $16.19.

Surrozen (NASDAQ:SRZN) last issued its earnings results on Wednesday, November 6th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.77) by $2.33. The company had revenue of $10.00 million during the quarter. Analysts expect that Surrozen will post -7.16 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Surrozen

Hedge funds have recently bought and sold shares of the company. Armistice Capital LLC acquired a new stake in Surrozen in the 2nd quarter valued at about $2,080,000. Nantahala Capital Management LLC purchased a new stake in shares of Surrozen in the second quarter valued at about $2,050,000. Stonepine Capital Management LLC grew its position in shares of Surrozen by 66.5% in the third quarter. Stonepine Capital Management LLC now owns 110,000 shares of the company’s stock valued at $1,318,000 after purchasing an additional 43,916 shares during the last quarter. Finally, CVI Holdings LLC purchased a new position in shares of Surrozen during the 2nd quarter worth approximately $711,000. 66.57% of the stock is owned by hedge funds and other institutional investors.

Surrozen Company Profile

Surrozen, Inc, a clinical stage biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. The company is developing antibody-based therapeutics which targets various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system.